1. Home
  2. PECO vs DNTH Comparison

PECO vs DNTH Comparison

Compare PECO & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Phillips Edison & Company Inc.

PECO

Phillips Edison & Company Inc.

HOLD

Current Price

$40.43

Market Cap

5.2B

Sector

Real Estate

ML Signal

HOLD

Logo Dianthus Therapeutics Inc.

DNTH

Dianthus Therapeutics Inc.

HOLD

Current Price

$109.45

Market Cap

4.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PECO
DNTH
Founded
1991
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.2B
4.5B
IPO Year
2010
2018

Fundamental Metrics

Financial Performance
Metric
PECO
DNTH
Price
$40.43
$109.45
Analyst Decision
Buy
Strong Buy
Analyst Count
7
13
Target Price
$39.71
$121.00
AVG Volume (30 Days)
850.0K
795.1K
Earning Date
04-23-2026
05-06-2026
Dividend Yield
3.26%
N/A
EPS Growth
74.51
N/A
EPS
0.56
N/A
Revenue
$726,594,000.00
$2,036,000.00
Revenue This Year
$5.82
N/A
Revenue Next Year
$3.81
$29.48
P/E Ratio
$71.68
N/A
Revenue Growth
9.86
N/A
52 Week Low
$32.98
$19.84
52 Week High
$44.38
$114.55

Technical Indicators

Market Signals
Indicator
PECO
DNTH
Relative Strength Index (RSI) 36.82 57.06
Support Level $40.18 $79.27
Resistance Level $42.54 $114.55
Average True Range (ATR) 0.80 5.58
MACD -0.32 -0.21
Stochastic Oscillator 22.05 71.41

Price Performance

Historical Comparison
PECO
DNTH

About PECO Phillips Edison & Company Inc.

Phillips Edison & Co Inc is a real estate investment trust. The company also operates a third-party investment management business providing property management and advisory services to four unconsolidated institutional joint ventures, in which it has a partial ownership interest, and one private fund. It invests in well-occupied, grocery-anchored neighborhood and community shopping centers. It holds an integrated in-house operating platform built on a market of expertise designed to optimize property value and consistently deliver a great shopping experience.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Share on Social Networks: